Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 103 entries
Sorted by: Best Match Show Resources per page
Problem structuring and multiple criteria decision analysis

Science interventions

Belton V, Stewart T.
GSID: PKPLT310cN0J
V Belton, T Stewart - Trends in multiple criteria decision analysis, 2010 - Springer

This chapter addresses two complementary themes in relation to problem structuring and MCDA. The first and primary theme highlights the nature and importance of problem …

Cite
Belton, V., & Stewart, T. (2010). Problem structuring and multiple criteria decision analysis. Trends in multiple criteria decision analysis, 209-239.
Belton, Valerie, and Theodor Stewart. "Problem structuring and multiple criteria decision analysis." Trends in multiple criteria decision analysis (2010): 209-239.
Copy Download .nbib Format: MLA
Okul öncesi öğretmen ve öğretmen adaylarının okul öncesi öğretmen yetiştirme lisans programı hakkında görüş ve önerileri

Undergraduate training programs stem

Bartan M.
GSID: czD9_2ZpOfUJ
M Bartan - Dumlupınar Üniversitesi Eğitim Bilimleri Enstitüsü …, 2019 - dergipark.org.tr

… about the pre-school teacher training undergraduate program. In this study, descriptive … dersi çocukları tanıma teknikleri kodlama stem okul öncesinde ölçme değerlendirme değerler …

Cite
Bartan, M. (2019). Okul öncesi öğretmen ve öğretmen adaylarının okul öncesi öğretmen yetiştirme lisans programı hakkında görüş ve önerileri. Dumlupınar Üniversitesi Eğitim Bilimleri Enstitüsü Dergisi, 3(1), 24-36.
Bartan, Murat. "Okul öncesi öğretmen ve öğretmen adaylarının okul öncesi öğretmen yetiştirme lisans programı hakkında görüş ve önerileri." Dumlupınar Üniversitesi Eğitim Bilimleri Enstitüsü Dergisi 3.1 (2019): 24-36.
Copy Download .nbib Format: MLA
Extraspinal sacrococcygeal ependymoma masquerading as sacrococcygeal teratoma in the pediatric patient.

Pediatric surgery international

Amin R, Berdan E, Knipstein J, Jarzembowski J, Siddiqui S.
PMID: 29138922
Pediatr Surg Int. 2018 Jan;34(1):109-112. doi: 10.1007/s00383-017-4214-0. Epub 2017 Nov 14.

No abstract available.

Cite
Amin R, Berdan E, Knipstein J, et al. Extraspinal sacrococcygeal ependymoma masquerading as sacrococcygeal teratoma in the pediatric patient. Pediatr Surg Int. 2017;34(1):109-112doi: 10.1007/s00383-017-4214-0.
Amin, R., Berdan, E., Knipstein, J., Jarzembowski, J., & Siddiqui, S. (2018). Extraspinal sacrococcygeal ependymoma masquerading as sacrococcygeal teratoma in the pediatric patient. Pediatric surgery international, 34(1), 109-112. https://doi.org/10.1007/s00383-017-4214-0
Amin, Ruchi, et al. "Extraspinal sacrococcygeal ependymoma masquerading as sacrococcygeal teratoma in the pediatric patient." Pediatric surgery international vol. 34,1 (2018): 109-112. doi: https://doi.org/10.1007/s00383-017-4214-0
Amin R, Berdan E, Knipstein J, Jarzembowski J, Siddiqui S. Extraspinal sacrococcygeal ependymoma masquerading as sacrococcygeal teratoma in the pediatric patient. Pediatr Surg Int. 2018 Jan;34(1):109-112. doi: 10.1007/s00383-017-4214-0. Epub 2017 Nov 14. PMID: 29138922.
Copy Download .nbib Format: NLM
WAH-1/AIF regulates mitochondrial oxidative phosphorylation in the nematode .

Cell death discovery

Troulinaki K, Büttner S, Marsal Cots A, Maida S, Meyer K, Bertan F, Gioran A, Piazzesi A, Fornarelli A, Nicotera P, Bano D.
PMID: 29531799
Cell Death Discov. 2018 Jan 29;4:2. doi: 10.1038/s41420-017-0005-6. eCollection 2018 Dec.

Impaired mitochondrial energy metabolism contributes to a wide range of pathologic conditions, including neurodegenerative diseases. Mitochondrial apoptosis-inducing factor (AIF) is required for the correct maintenance of mitochondrial electron transport chain. An emerging body of clinical evidence indicates that several...

Cite
Troulinaki K, Büttner S, Marsal Cots A, et al. WAH-1/AIF regulates mitochondrial oxidative phosphorylation in the nematode . Cell Death Discov. 2018;4:2doi: 10.1038/s41420-017-0005-6.
Troulinaki, K., Büttner, S., Marsal Cots, A., Maida, S., Meyer, K., Bertan, F., Gioran, A., Piazzesi, A., Fornarelli, A., Nicotera, P., & Bano, D. (2018). WAH-1/AIF regulates mitochondrial oxidative phosphorylation in the nematode . Cell death discovery, 42. https://doi.org/10.1038/s41420-017-0005-6
Troulinaki, Kostoula, et al. "WAH-1/AIF regulates mitochondrial oxidative phosphorylation in the nematode ." Cell death discovery vol. 4 (2018): 2. doi: https://doi.org/10.1038/s41420-017-0005-6
Troulinaki K, Büttner S, Marsal Cots A, Maida S, Meyer K, Bertan F, Gioran A, Piazzesi A, Fornarelli A, Nicotera P, Bano D. WAH-1/AIF regulates mitochondrial oxidative phosphorylation in the nematode . Cell Death Discov. 2018 Jan 29;4:2. doi: 10.1038/s41420-017-0005-6. eCollection 2018 Dec. PMID: 29531799; PMCID: PMC5841390.
Copy Download .nbib Format: NLM
Catalytic Reduction of Nitrous Oxide by the Low-Symmetry Pt.

The journal of physical chemistry. A

Hernández E, Bertin V, Soto J, Miralrio A, Castro M.
PMID: 29437397
J Phys Chem A. 2018 Mar 01;122(8):2209-2220. doi: 10.1021/acs.jpca.7b11055. Epub 2018 Feb 21.

The search for a catalyst for the reduction of nitrous oxide (N

Cite
Hernández E, Bertin V, Soto J, et al. Catalytic Reduction of Nitrous Oxide by the Low-Symmetry Pt. J Phys Chem A. 2018;122(8):2209-2220doi: 10.1021/acs.jpca.7b11055.
Hernández, E., Bertin, V., Soto, J., Miralrio, A., & Castro, M. (2018). Catalytic Reduction of Nitrous Oxide by the Low-Symmetry Pt. The journal of physical chemistry. A, 122(8), 2209-2220. https://doi.org/10.1021/acs.jpca.7b11055
Hernández, Erendida, et al. "Catalytic Reduction of Nitrous Oxide by the Low-Symmetry Pt." The journal of physical chemistry. A vol. 122,8 (2018): 2209-2220. doi: https://doi.org/10.1021/acs.jpca.7b11055
Hernández E, Bertin V, Soto J, Miralrio A, Castro M. Catalytic Reduction of Nitrous Oxide by the Low-Symmetry Pt. J Phys Chem A. 2018 Mar 01;122(8):2209-2220. doi: 10.1021/acs.jpca.7b11055. Epub 2018 Feb 21. PMID: 29437397.
Copy Download .nbib Format: NLM
Therapeutic Drug Monitoring in the Era of Precision Medicine: Achievements, Gaps, and Perspectives-An Interview in Honor of Professor Charles Pippenger.

Therapeutic drug monitoring

Wong SH, Marquet P, Cattaneo D, Svinarov D, Bergan S, Walson P, Vinks AA, Shipkova M.
PMID: 34654029
Ther Drug Monit. 2021 Dec 01;43(6):719-727. doi: 10.1097/FTD.0000000000000932.

No abstract available.

Cite
Wong SH, Marquet P, Cattaneo D, et al. Therapeutic Drug Monitoring in the Era of Precision Medicine: Achievements, Gaps, and Perspectives-An Interview in Honor of Professor Charles Pippenger. Ther Drug Monit. 2021;43(6):719-727doi: 10.1097/FTD.0000000000000932.
Wong, S. H., Marquet, P., Cattaneo, D., Svinarov, D., Bergan, S., Walson, P., Vinks, A. A., & Shipkova, M. (2021). Therapeutic Drug Monitoring in the Era of Precision Medicine: Achievements, Gaps, and Perspectives-An Interview in Honor of Professor Charles Pippenger. Therapeutic drug monitoring, 43(6), 719-727. https://doi.org/10.1097/FTD.0000000000000932
Wong, Steven H, et al. "Therapeutic Drug Monitoring in the Era of Precision Medicine: Achievements, Gaps, and Perspectives-An Interview in Honor of Professor Charles Pippenger." Therapeutic drug monitoring vol. 43,6 (2021): 719-727. doi: https://doi.org/10.1097/FTD.0000000000000932
Wong SH, Marquet P, Cattaneo D, Svinarov D, Bergan S, Walson P, Vinks AA, Shipkova M. Therapeutic Drug Monitoring in the Era of Precision Medicine: Achievements, Gaps, and Perspectives-An Interview in Honor of Professor Charles Pippenger. Ther Drug Monit. 2021 Dec 01;43(6):719-727. doi: 10.1097/FTD.0000000000000932. PMID: 34654029.
Copy Download .nbib Format: NLM
Deletion of lysophosphatidylcholine acyltransferase 3 in myeloid cells worsens hepatic steatosis after a high-fat diet.

Journal of lipid research

Bourgeois T, Jalil A, Thomas C, Magnani C, Le Guern N, Gautier T, Pais de Barros JP, Bergas V, Choubley H, Mazzeo L, Menegaut L, Josiane Lebrun L, Van Dongen K, Xolin M, Jourdan T, Buch C, Labbé J, Saas P, Lagrost L, Masson D, Grober J.
PMID: 33518513
J Lipid Res. 2020 Dec 17;62:100013. doi: 10.1194/jlr.RA120000737. Epub 2020 Dec 17.

Recent studies have highlighted an important role for lysophosphatidylcholine acyltransferase 3 (LPCAT3) in controlling the PUFA composition of cell membranes in the liver and intestine. In these organs, LPCAT3 critically supports cell-membrane-associated processes such as lipid absorption or lipoprotein...

Cite
Bourgeois T, Jalil A, Thomas C, et al. Deletion of lysophosphatidylcholine acyltransferase 3 in myeloid cells worsens hepatic steatosis after a high-fat diet. J Lipid Res. 2020;62:100013doi: 10.1194/jlr.RA120000737.
Bourgeois, T., Jalil, A., Thomas, C., Magnani, C., Le Guern, N., Gautier, T., Pais de Barros, J. P., Bergas, V., Choubley, H., Mazzeo, L., Menegaut, L., Josiane Lebrun, L., Van Dongen, K., Xolin, M., Jourdan, T., Buch, C., Labbé, J., Saas, P., Lagrost, L., Masson, D., & Grober, J. (2020). Deletion of lysophosphatidylcholine acyltransferase 3 in myeloid cells worsens hepatic steatosis after a high-fat diet. Journal of lipid research, 62100013. https://doi.org/10.1194/jlr.RA120000737
Bourgeois, Thibaut, et al. "Deletion of lysophosphatidylcholine acyltransferase 3 in myeloid cells worsens hepatic steatosis after a high-fat diet." Journal of lipid research vol. 62 (2020): 100013. doi: https://doi.org/10.1194/jlr.RA120000737
Bourgeois T, Jalil A, Thomas C, Magnani C, Le Guern N, Gautier T, Pais de Barros JP, Bergas V, Choubley H, Mazzeo L, Menegaut L, Josiane Lebrun L, Van Dongen K, Xolin M, Jourdan T, Buch C, Labbé J, Saas P, Lagrost L, Masson D, Grober J. Deletion of lysophosphatidylcholine acyltransferase 3 in myeloid cells worsens hepatic steatosis after a high-fat diet. J Lipid Res. 2020 Dec 17;62:100013. doi: 10.1194/jlr.RA120000737. Epub 2020 Dec 17. PMID: 33518513; PMCID: PMC7859853.
Copy Download .nbib Format: NLM
Revealing the Distribution of Metal Carboxylates in Oil Paint from the Micro- to Nanoscale.

Angewandte Chemie (International ed. in English)

Ma X, Beltran V, Ramer G, Pavlidis G, Parkinson DY, Thoury M, Meldrum T, Centrone A, Berrie BH.
PMID: 31226237
Angew Chem Int Ed Engl. 2019 Aug 19;58(34):11652-11656. doi: 10.1002/anie.201903553. Epub 2019 Jul 24.

Oil paints comprise pigments, drying oils, and additives that together confer desirable properties, but can react to form metal carboxylates (soaps) that may damage artworks over time. To obtain information on soap formation and aggregation, we introduce a new...

Cite
Ma X, Beltran V, Ramer G, et al. Revealing the Distribution of Metal Carboxylates in Oil Paint from the Micro- to Nanoscale. Angew Chem Int Ed Engl. 2019;58(34):11652-11656doi: 10.1002/anie.201903553.
Ma, X., Beltran, V., Ramer, G., Pavlidis, G., Parkinson, D. Y., Thoury, M., Meldrum, T., Centrone, A., & Berrie, B. H. (2019). Revealing the Distribution of Metal Carboxylates in Oil Paint from the Micro- to Nanoscale. Angewandte Chemie (International ed. in English), 58(34), 11652-11656. https://doi.org/10.1002/anie.201903553
Ma, Xiao, et al. "Revealing the Distribution of Metal Carboxylates in Oil Paint from the Micro- to Nanoscale." Angewandte Chemie (International ed. in English) vol. 58,34 (2019): 11652-11656. doi: https://doi.org/10.1002/anie.201903553
Ma X, Beltran V, Ramer G, Pavlidis G, Parkinson DY, Thoury M, Meldrum T, Centrone A, Berrie BH. Revealing the Distribution of Metal Carboxylates in Oil Paint from the Micro- to Nanoscale. Angew Chem Int Ed Engl. 2019 Aug 19;58(34):11652-11656. doi: 10.1002/anie.201903553. Epub 2019 Jul 24. PMID: 31226237.
Copy Download .nbib Format: NLM
HER3 Is an Actionable Target in Advanced Prostate Cancer.

Cancer research

Gil V, Miranda S, Riisnaes R, Gurel B, D'Ambrosio M, Vasciaveo A, Crespo M, Ferreira A, Brina D, Troiani M, Sharp A, Sheehan B, Christova R, Seed G, Figueiredo I, Lambros M, Dolling D, Rekowski J, Alajati A, Clarke M, Pereira R, Flohr P, Fowler G, Boysen G, Sumanasuriya S, Bianchini D, Rescigno P, Aversa C, Tunariu N, Guo C, Paschalis A, Bertan C, Buroni L, Ning J, Carreira S, Workman P, Swain A, Califano A, Shen MM, Alimonti A, Neeb A, Welti J, Yuan W, de Bono J.
PMID: 34753775
Cancer Res. 2021 Dec 15;81(24):6207-6218. doi: 10.1158/0008-5472.CAN-21-3360. Epub 2021 Nov 09.

It has been recognized for decades that ERBB signaling is important in prostate cancer, but targeting ERBB receptors as a therapeutic strategy for prostate cancer has been ineffective clinically. However, we show here that membranous HER3 protein is commonly...

Cite
Gil V, Miranda S, Riisnaes R, et al. HER3 Is an Actionable Target in Advanced Prostate Cancer. Cancer Res. 2021;81(24):6207-6218doi: 10.1158/0008-5472.CAN-21-3360.
Gil, V., Miranda, S., Riisnaes, R., Gurel, B., D'Ambrosio, M., Vasciaveo, A., Crespo, M., Ferreira, A., Brina, D., Troiani, M., Sharp, A., Sheehan, B., Christova, R., Seed, G., Figueiredo, I., Lambros, M., Dolling, D., Rekowski, J., Alajati, A., Clarke, M., Pereira, R., Flohr, P., Fowler, G., Boysen, G., Sumanasuriya, S., Bianchini, D., Rescigno, P., Aversa, C., Tunariu, N., Guo, C., Paschalis, A., Bertan, C., Buroni, L., Ning, J., Carreira, S., Workman, P., Swain, A., Califano, A., Shen, M. M., Alimonti, A., Neeb, A., Welti, J., Yuan, W., de Bono, J. (2021). HER3 Is an Actionable Target in Advanced Prostate Cancer. Cancer research, 81(24), 6207-6218. https://doi.org/10.1158/0008-5472.CAN-21-3360
Gil, Veronica, et al. "HER3 Is an Actionable Target in Advanced Prostate Cancer." Cancer research vol. 81,24 (2021): 6207-6218. doi: https://doi.org/10.1158/0008-5472.CAN-21-3360
Gil V, Miranda S, Riisnaes R, Gurel B, D'Ambrosio M, Vasciaveo A, Crespo M, Ferreira A, Brina D, Troiani M, Sharp A, Sheehan B, Christova R, Seed G, Figueiredo I, Lambros M, Dolling D, Rekowski J, Alajati A, Clarke M, Pereira R, Flohr P, Fowler G, Boysen G, Sumanasuriya S, Bianchini D, Rescigno P, Aversa C, Tunariu N, Guo C, Paschalis A, Bertan C, Buroni L, Ning J, Carreira S, Workman P, Swain A, Califano A, Shen MM, Alimonti A, Neeb A, Welti J, Yuan W, de Bono J. HER3 Is an Actionable Target in Advanced Prostate Cancer. Cancer Res. 2021 Dec 15;81(24):6207-6218. doi: 10.1158/0008-5472.CAN-21-3360. Epub 2021 Nov 09. PMID: 34753775.
Copy Download .nbib Format: NLM
Quantification of Lung Fibrosis in IPF-Like Mouse Model and Pharmacological Response to Treatment by Micro-Computed Tomography.

Frontiers in pharmacology

Ruscitti F, Ravanetti F, Bertani V, Ragionieri L, Mecozzi L, Sverzellati N, Silva M, Ruffini L, Menozzi V, Civelli M, Villetti G, Stellari FF.
PMID: 32792953
Front Pharmacol. 2020 Jul 21;11:1117. doi: 10.3389/fphar.2020.01117. eCollection 2020.

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive degenerative lung disease leading to respiratory failure and death. Although anti-fibrotic drugs are now available for treating IPF, their clinical efficacy is limited and lung transplantation remains the only modality to...

Cite
Ruscitti F, Ravanetti F, Bertani V, et al. Quantification of Lung Fibrosis in IPF-Like Mouse Model and Pharmacological Response to Treatment by Micro-Computed Tomography. Front Pharmacol. 2020;11:1117doi: 10.3389/fphar.2020.01117.
Ruscitti, F., Ravanetti, F., Bertani, V., Ragionieri, L., Mecozzi, L., Sverzellati, N., Silva, M., Ruffini, L., Menozzi, V., Civelli, M., Villetti, G., & Stellari, F. F. (2020). Quantification of Lung Fibrosis in IPF-Like Mouse Model and Pharmacological Response to Treatment by Micro-Computed Tomography. Frontiers in pharmacology, 111117. https://doi.org/10.3389/fphar.2020.01117
Ruscitti, Francesca, et al. "Quantification of Lung Fibrosis in IPF-Like Mouse Model and Pharmacological Response to Treatment by Micro-Computed Tomography." Frontiers in pharmacology vol. 11 (2020): 1117. doi: https://doi.org/10.3389/fphar.2020.01117
Ruscitti F, Ravanetti F, Bertani V, Ragionieri L, Mecozzi L, Sverzellati N, Silva M, Ruffini L, Menozzi V, Civelli M, Villetti G, Stellari FF. Quantification of Lung Fibrosis in IPF-Like Mouse Model and Pharmacological Response to Treatment by Micro-Computed Tomography. Front Pharmacol. 2020 Jul 21;11:1117. doi: 10.3389/fphar.2020.01117. eCollection 2020. PMID: 32792953; PMCID: PMC7385278.
Copy Download .nbib Format: NLM
The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine.

Cell

Dickson D, Johnson J, Bergan R, Owens R, Subbiah V, Kurzrock R.
PMID: 31951522
Cell. 2020 Jan 09;180(1):9-14. doi: 10.1016/j.cell.2019.12.009.

This commentary introduces a new clinical trial construct, the Master Observational Trial (MOT), which hybridizes the power of molecularly based master interventional protocols with the breadth of real-world data. The MOT provides a clinical venue to allow molecular medicine...

Cite
Dickson D, Johnson J, Bergan R, et al. The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine. Cell. 2020;180(1):9-14doi: 10.1016/j.cell.2019.12.009.
Dickson, D., Johnson, J., Bergan, R., Owens, R., Subbiah, V., & Kurzrock, R. (2020). The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine. Cell, 180(1), 9-14. https://doi.org/10.1016/j.cell.2019.12.009
Dickson, Dane, et al. "The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine." Cell vol. 180,1 (2020): 9-14. doi: https://doi.org/10.1016/j.cell.2019.12.009
Dickson D, Johnson J, Bergan R, Owens R, Subbiah V, Kurzrock R. The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine. Cell. 2020 Jan 09;180(1):9-14. doi: 10.1016/j.cell.2019.12.009. PMID: 31951522.
Copy Download .nbib Format: NLM
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial.

Cancer discovery

Carreira S, Porta N, Arce-Gallego S, Seed G, Llop-Guevara A, Bianchini D, Rescigno P, Paschalis A, Bertan C, Baker C, Goodall J, Miranda S, Riisnaes R, Figueiredo I, Ferreira A, Pereira R, Crespo M, Gurel B, Nava Rodrigues D, Pettitt SJ, Yuan W, Serra V, Rekowski J, Lord CJ, Hall E, Mateo J, de Bono JS.
PMID: 34045297
Cancer Discov. 2021 Nov;11(11):2812-2827. doi: 10.1158/2159-8290.CD-21-0007. Epub 2021 May 27.

PARP inhibitors are approved for treating advanced prostate cancers (APC) with various defective DNA repair genes; however, further studies to clinically qualify predictive biomarkers are warranted. Herein we analyzed TOPARP-B phase II clinical trial samples, evaluating whole-exome and low-pass...

Cite
Carreira S, Porta N, Arce-Gallego S, et al. Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. Cancer Discov. 2021;11(11):2812-2827doi: 10.1158/2159-8290.CD-21-0007.
Carreira, S., Porta, N., Arce-Gallego, S., Seed, G., Llop-Guevara, A., Bianchini, D., Rescigno, P., Paschalis, A., Bertan, C., Baker, C., Goodall, J., Miranda, S., Riisnaes, R., Figueiredo, I., Ferreira, A., Pereira, R., Crespo, M., Gurel, B., Nava Rodrigues, D., Pettitt, S. J., Yuan, W., Serra, V., Rekowski, J., Lord, C. J., Hall, E., Mateo, J., & de Bono, J. S. (2021). Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. Cancer discovery, 11(11), 2812-2827. https://doi.org/10.1158/2159-8290.CD-21-0007
Carreira, Suzanne, et al. "Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial." Cancer discovery vol. 11,11 (2021): 2812-2827. doi: https://doi.org/10.1158/2159-8290.CD-21-0007
Carreira S, Porta N, Arce-Gallego S, Seed G, Llop-Guevara A, Bianchini D, Rescigno P, Paschalis A, Bertan C, Baker C, Goodall J, Miranda S, Riisnaes R, Figueiredo I, Ferreira A, Pereira R, Crespo M, Gurel B, Nava Rodrigues D, Pettitt SJ, Yuan W, Serra V, Rekowski J, Lord CJ, Hall E, Mateo J, de Bono JS. Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. Cancer Discov. 2021 Nov;11(11):2812-2827. doi: 10.1158/2159-8290.CD-21-0007. Epub 2021 May 27. PMID: 34045297.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 103 entries